Orchid Pharma and its wholly owned subsidiary, Orchid Bio Pharma have entered into a Memorandum of Understanding (MoU) with an overseas technology provider for in-licensing 7ACA technology.
Orchid Bio Pharma has been granted approval by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product 7 ACA.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU